Ortin Global Ltd
Incorporated in 1986, Ortin Laboratories Ltd is engaged in the manufacturing and trading of Pharmaceuticals, Drugs and Intermediates.
- Market Cap ₹ 15.5 Cr.
- Current Price ₹ 19.0
- High / Low ₹ 26.4 / 16.2
- Stock P/E
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Promoter holding is low: 1.23%
- Promoter holding has decreased over last 3 years: -14.4%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | -12% |
| 1 Year: | -4% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Net Cash Flow |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
19 Nov - Publishing of un-audited financials for the quarter ended 30-09-2024 in news papers
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Publishing of un-audited financials for the quarter ended 30-09-2024 in news papers
- Un-Audited Results For The Quarter Ended On 30-09-2024 13 Nov
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 13-11-2024
13 Nov - Board approved unaudited financial results for Q2 2024.
-
Board Meeting Intimation for Un-Audited Financial Results For The Quarter And Half Year Ended 30.09.2024
4 Nov - Board meeting scheduled for financial results on 13th Nov 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:
a) Formulations:[1] Anti Diabetics, Anti Allergics, Anti Anginal & Cardio Vascular, Sedatives & Tranquillizers, Analgesics & Antipyretics Anti Helmenthetics, Anti-fungal, Anti Biotics-Quinolones, Anti Biotic-Penicillin, Chemo Therapeutics, Cephalosporins, Macrolides, Anti-ulcerants & Antacids, Anti-spasmodic, Calcium preparations, Iron preparations, Gynec, Anti -Arthritic Drugs, Protein supplements, Enzymes, Vitamins, Psychiatry, Appetizers, Anti-Retroviral
b) API Intermediates:[2] Anti retro viral, Anti Diabetics, Antifungal, Antacids & Anti ulcerant, Analgesics & Antipyretics, Anti - Biotic, Anti malarial, Fine chemicals, Grignard & alkali metal products
c) Merchant Export Trading:[3]
Company supplies pharmaceutical formulations comprising tablets, capsules, liquid orals, ear
drops, nasal drops, ointments, liquid injections, sterile dry powder injections, pharmaceutical veterinary tablets, dry syrups, sterile powder.